Alzamend Neuro (ALZN) revenue and earnings history
Alzamend Neuro's annual figures for 7 fiscal years, as filed with the SEC.
Revenue and net income, 7 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026ended Apr 30, 2026 | — | −$8.77M | −$8.77M | −$8.07M | — | — | $708K | — | — | $711K | — | 10-K |
| 2025ended Apr 30, 2025 | — |
The latest quarter, insider trades and fund moves: Alzamend Neuro (ALZN) on OQRO.
Common questions
Has Alzamend Neuro been profitable?
It reported a net loss in 7 of the years shown (2020, 2021, 2022, 2023, 2024, 2025, 2026). The highest net income was −$4.41M in fiscal 2020.
Does Alzamend Neuro buy back shares or pay dividends?
None of the 7 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Why is earnings per share not in this table?
Each year's figure here comes from the newest annual report that states it. After a stock split, earlier reports and later reports state per-share figures on different share counts, so a column of EPS would mix the two. Net income is not affected by splits.
Where these figures come from
The SEC’s companyfacts data: every figure Alzamend Neuro tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.